Efficacy and safety analysis of anlotinib combined with PD-1 inhibitors in advanced non-small cell lung cancer: a retrospective cohort study

por Ye, Xuanting, Huang, Aimi, Zhou, Yan, Kuang, Yanbin, Wang, Weimin, Gu, Aiqin, Xu, Ling
Publicado 2023

Epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors combined with chemotherapy in first‐line treatment in an advanced non‐small cell lung cancer patient with EGFR se...

por Huang, Aimi, Li, Rong, Zhao, Jikai, Wang, Xiaofei, Jin, Bo, Niu, Yanjie, Zhang, Jie, Jiang, Liyan, Han, Baohui
Publicado 2016

Analysis of the clinical effect of osimertinib on 90 cases with advanced lung adenocarcinoma

por Gao, Zhiqiang, Wang, Weimin, Gu, Aiqin, Lu, Jianhong, Huang, Aimi, Xiong, Liwen, Han, Baohui, Jiang, Liyan, Shi, Chunlei
Publicado 2020

Afatinib 30 mg in the treatment of common and uncommon EGFR-mutated advanced lung adenocarcinomas: a retrospective, single-center, longitudinal study

por Qian, Jie, Ye, Xuanting, Huang, Aimi, Qin, Ruoyan, Cai, Yuqing, Xue, Yiqian, Zhang, Shi, Wang, Weimin, Xiong, Liwen, Gu, Aiqin
Publicado 2022

Whole-Exome Sequencing on Circulating Tumor Cells Explores Platinum-Drug Resistance Mutations in Advanced Non-small Cell Lung Cancer

por Chang, Yuanyuan, Wang, Yin, Li, Boyi, Lu, Xingzhong, Wang, Ruiru, Li, Hui, Yan, Bo, Gu, Aiqin, Wang, Weimin, Huang, Aimi, Wu, Shuangxiu, Li, Rong
Publicado 2021